Should You Buy Takeda Pharmaceutical Co Ltd (TAK) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Takeda Pharmaceutical Co Ltd (TAK) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the stock has some positive developments, such as recent product launches and collaborations, the company's declining financial performance and lack of strong trading signals suggest a cautious approach. Holding the stock or waiting for better entry points might be more prudent.
Technical Analysis
The technical indicators show mixed signals. The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 61.062, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance levels (R1: 16.421, R2: 16.586), which could limit short-term upside potential.
Analyst Ratings and Price Target Trends
Analysts have a positive view of Takeda's partnerships and pipeline expansion, as highlighted by H.C. Wainwright's commentary. However, this optimism is more focused on Xoma's assets rather than Takeda's standalone performance.
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18 USD with a low forecast of 18 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18 USD with a low forecast of 18 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 16.690
Current: 16.690
